Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18; male or female~* Early breast cancer (stage I-3c)~* Documented HER2+ tumor: HER2 immunohistochemistry (IHC) 3+ or ISH+~* Prior course of adjuvant trastuzumab given \>2 weeks and ≤1 year from enrollment~* No evidence of local/regional recurrence or metastatic disease~* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1~* Male patients with female partners of childbearing potential must agree and commit to use a condom and women of childbearing potential must not be pregnant and must agree and commit to the use of a highly effective non-hormonal method of contraception~* Left ventricular ejection fraction (LVEF) ≥50% measured by multiple-gated acquisition scan (MUGA) or ECHO~Exclusion Criteria:~* Major surgery \< 30 days~* Chemotherapy, investigational agents, other cancer therapy (except hormonal therapy) \< 14 days~* Corrected QT Interval (QTc) \>0.450 seconds (males) or \>0.470 (females) or other active cardiac disease~* Significant chronic GI disorder with diarrhea as a major symptom~* Active, unresolved infections~* Currently pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loperamide (Type: EXPERIMENTAL): 240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Loperamide daily for two 28-day cycles and then as needed.
- Budesonide and Loperamide (Type: EXPERIMENTAL): 240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Anti-inflammatory treatment for 1 cycle and Loperamide to be administered daily for two 28-day cycles and then as needed, thereafter.
- Colestipol and Loperamide (Type: EXPERIMENTAL): 240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter.
- Colestipol with Loperamide as needed (Type: EXPERIMENTAL): 240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered as needed.
- Neratinib Dose Escalation 1 (Type: EXPERIMENTAL): 120 mg Neratinib for Week 1, followed by 160 mg Neratinib starting for Week 2, followed by 240 mg Neratinib starting at Week 3 and thereafter (C1D15 to End of Treatment). Loperamide administered as needed.
- Neratinib Dose Escalation 2 (Type: EXPERIMENTAL): 160 mg neratinib for the first 2 weeks, followed by 200 mg neratinib for the next 2 weeks, followed by 240 mg neratinib thereafter (C2D1 to End of treatment. Loperamide will be administered on an as-needed basis only.

Based on this trial design, predict the completion outcome and termination type (if applicable).